JXR announced significant progress in the number of in vitro fertilization (IVF) egg retrieval cycles for the nine months ending September 30, 2025. The company maintains strong confidence in the long-term development prospects of the industry and its future growth, which is supported by a solid industry foundation, ongoing favorable national policies, and continuous efforts to enhance clinical outcomes, optimize patient care, and diversify service offerings. In the third quarter of 2025, driven by a series of management and operational improvements and reflecting a positive trend, the overall decline in the group’s IVF egg retrieval cycles slowed, narrowing from a decrease of -8.3% from the first half of 2024 to the first half of 2025, to -5.2% from the first three quarters of 2024 to the first three quarters of 2025. Specifically, the IVF egg retrieval cycles at the group's flagship hospital in Chengdu reduced its decline from -6.1% in the first half of 2025 to -1.9% for the nine months ending September 30, 2025. Meanwhile, the improvement at the group's Shenzhen hospital is slower compared to Chengdu, due to preparations for the hospital relocation planned for the end of 2025. In the U.S. market, the postponement of California Senate Bill SB729, which requires commercial insurance to cover assisted reproduction, has led to a delay in IVF egg retrieval cycles, resulting in a decline that aligns with expectations for the group’s U.S. operations.